In a significant development in the pharmaceutical industry, Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), have announced the approval of SELARSDI (ustekinumab-aekn) injection by the U.S. Food and Drug Administration (FDA). This approval marks SELARSDI as a biosimilar to Stelara, designed for the treatment […]
Alvotech and Teva Pharmaceuticals have achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of SIMLANDI (adalimumab-ryvk) injection. This approval positions SIMLANDI as an interchangeable biosimilar to Humira, a leading treatment for various arthritis and inflammatory conditions. The approval covers a wide range of conditions, including adult rheumatoid arthritis, juvenile idiopathic […]
